- Home
- TSI vs FENC Comparison
TSI vs FENC Comparison
Compare TSI & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSI
- FENC
- Stock Information
- Founded
- TSI 1987
- FENC 1996
- Country
- TSI United States
- FENC United States
- Employees
- TSI N/A
- FENC N/A
- Industry
- TSI Investment Managers
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TSI Finance
- FENC Health Care
- Exchange
- TSI Nasdaq
- FENC Nasdaq
- Market Cap
- TSI 234.6M
- FENC 229.8M
- IPO Year
- TSI N/A
- FENC 2001
- Fundamental
- Price
- TSI $4.90
- FENC $7.76
- Analyst Decision
- TSI
- FENC Strong Buy
- Analyst Count
- TSI 0
- FENC 2
- Target Price
- TSI N/A
- FENC $13.00
- AVG Volume (30 Days)
- TSI 106.8K
- FENC 86.3K
- Earning Date
- TSI 01-01-0001
- FENC 08-12-2025
- Dividend Yield
- TSI 7.46%
- FENC N/A
- EPS Growth
- TSI N/A
- FENC N/A
- EPS
- TSI N/A
- FENC N/A
- Revenue
- TSI N/A
- FENC $30,912,000.00
- Revenue This Year
- TSI N/A
- FENC $0.85
- Revenue Next Year
- TSI N/A
- FENC $55.16
- P/E Ratio
- TSI N/A
- FENC N/A
- Revenue Growth
- TSI N/A
- FENC N/A
- 52 Week Low
- TSI $4.48
- FENC $3.96
- 52 Week High
- TSI $4.87
- FENC $8.72
- Technical
- Relative Strength Index (RSI)
- TSI 29.71
- FENC 51.69
- Support Level
- TSI $4.90
- FENC $7.53
- Resistance Level
- TSI $4.94
- FENC $8.19
- Average True Range (ATR)
- TSI 0.04
- FENC 0.47
- MACD
- TSI -0.01
- FENC -0.12
- Stochastic Oscillator
- TSI 0.00
- FENC 19.67
About TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment and others.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.